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Abstract
The objective of this study was to compare rheumatoid arthritis (RA) disease activity and patient-reported outcomes (PROs) 
in a national sample of patients with RA with/without Sjögren’s syndrome (SS). Adults with RA from a large observational 
US registry (Corrona RA) with known SS status between 22 April 2010 and 31 July 2018 and a visit 12 (± 3) months after 
index date were identified (n = 36,256/52,757). SS status: determined from a yes/no variable reported at enrolment into the 
Corrona RA registry and follow-up visits. Index date: date that SS status was recorded (yes/no). Patients received biologic 
or targeted synthetic disease-modifying antirheumatic drugs as part of standard care. Patients with RA only were followed 
for ≥ 12 months to confirm the absence of SS. Patients were frequency- and propensity-score matched (PSM) 1:1 and strati-
fied by disease duration and treatment response-associated variables, respectively. Clinical Disease Activity Index (CDAI) 
and PROs 12 months after index visit were compared in patients with and without SS. Baseline characteristics in 283 pairs 
of PSM patients were balanced. Mean change in CDAI score was numerically lower in patients with RA and SS than patients 
with RA only (8.8 vs 9.3). Reductions in PROs of pain, fatigue and stiffness were two- to threefold lower for patients with 
RA and SS versus RA only. Reductions in RA disease activity and RA-related PROs were lower in patients with RA and 
SS versus those with RA only. Our data indicate that SS adds to treatment challenges; physicians may wish to consider SS 
status when managing patients with RA.
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Introduction
Sjögren’s syndrome (SS) is a systemic autoimmune disease 
that can occur independently or in conjunction with another 
autoimmune condition, such as rheumatoid arthritis (RA) [1, 
2]. SS has traditionally been thought of as either primary (SS 
only) or secondary; however, the terminology for secondary 
SS has recently evolved to be more descriptive, particularly 
because SS and other autoimmune diseases are co-existing 
conditions, rather than one being secondary to the other [2].
The current American College of Rheumatology (ACR) 
and European League Against Rheumatism (EULAR) treat-
ment guidelines for RA and the ACR/EULAR classification 
criteria for SS do not include recommendations for treating 
patients with both RA and SS [3–5]. However, patients with 
both RA and SS have an increased disease burden [6, 7] and 
a decreased quality of life [8] compared with patients with 
only one autoimmune disease. For example, patients with RA 
and SS are more likely to have a longer duration of RA and 
worse joint damage compared with patients with RA only [6, 
9]. Patients with SS alone are more likely to experience a nega-
tive impact on physical functioning (e.g., lifting and carrying, 
climbing stairs, bending and walking moderate distances) and 
social functioning (e.g., quality and quantity of social activities 
with others) than control subjects without dry eye disease or 
SS [8, 10].
The correlation of SS with increased disease burden in 
patients with RA includes an association with higher RA dis-
ease activity and anti-citrullinated protein antibody (ACPA) 
positivity (+) [6, 11]. ACPAs play a pivotal role in the pro-
gression of RA [11, 12], indicating a poor prognosis [4], more 
severe disease course and radiological destruction compared 
with patients with RA who are ACPA negative (−) [13]. How-
ever, there are limited data on the impact of ACPA positivity 
and SS status in patients with RA and SS [6, 9, 14, 15].
Evaluating real-world data from patients with RA and SS 
and patients with RA only may enable clinicians to understand 
the different needs of these populations. The primary objective 
of this study was to compare RA disease activity and patient-
reported outcomes (PROs) in patients from a national registry 
sample of patients with RA, with and without SS. A secondary 
objective was to compare RA disease activity and PROs in a 
sub-group of ACPA+ patients with RA, as measured by anti-
cyclic citrullinated peptide (anti-CCP), with and without SS.
Materials and methods
Data source
The Consortium of Rheumatology Researchers of North 
America (Corrona) RA registry is an independent, 
prospective, national, observational cohort in which stand-
ardized and uniform treatment and outcome data are col-
lected from treating rheumatologists at the time of a clinical 
encounter for treatment of patients with RA. Patients have 
been recruited from 182 private practices and academic sites 
across 42 US states, with 781 participating rheumatologists. 
As of June 2019, the Corrona RA registry included informa-
tion on 52,757 patients. Data on 397,236 patient visits and 
approximately 188,161 patient-years of follow-up observa-
tion time have been collected, with a mean patient follow-up 
of 4.5 (median 3.3) years. The characteristics of the Corrona 
registry have been described previously [16].
This study was carried out in accordance with the Dec-
laration of Helsinki. All participating investigators were 
required to obtain full institutional review board (IRB) 
approval for conducting non-interventional research involv-
ing human subjects. Sponsor approval and continuing 
review was obtained through a central IRB (New England 
Independent Review Board, NEIRB No. 120160610). For 
academic investigative sites that did not receive a waiver 
to use the central IRB, full board approval was obtained 
from the respective governing IRBs and documentation of 
approval was submitted to Corrona, LLC, prior to initiating 
any study procedures. All registry patients were required to 
provide written informed consent and authorization prior to 
participating.
Study population
This study included adult patients with rheumatologist-
diagnosed RA enrolled in the Corrona RA registry between 
22 April 2010 and 31 July 2018 (Fig. 1). SS status was cap-
tured by physicians at enrolment and follow-up visits using 
a provider form that included a yes/no question regarding 
the status of SS associated with RA. The presence of SS was 
determined clinically based upon the presence, or absence, 
of symptomatic dry eyes and/or mouth judged by the treat-
ing physician not to be related to medications. The index 
date was defined as the date the provider first reported SS 
status as yes (patients with RA and SS) or no (patients with 
RA only). Data were included if patients had at least one 
visit assessing SS status (SS associated with RA: yes/no) 
and at least 12 months of follow-up after index date. If data 
were available for more than one visit, the visit closest to the 
12-month post-index date was used. Both patients with and 
without SS were required to have initiated a biologic (b) or 
targeted synthetic (ts) disease-modifying antirheumatic drug 
(DMARD). Patients without b/tsDMARD initiation or with 
missing SS information were excluded.
1241Rheumatology International (2020) 40:1239–1248 
1 3
Study assessments
Patients were randomly frequency matched 1:1 (patients 
with RA and SS and patients with RA only) based on 
the duration of RA (< 2, ≥ 2 to < 5, ≥ 5 to < 10, ≥ 10 
to < 15, ≥ 15 to < 20, ≥ 20 to < 30 and ≥ 30 years). Due to 
residual imbalance after frequency matching, frequency-
matched patients were pooled together and propensity-
score matched (PSM) 1:1 based on a logistic regression 
model-predicting group (RA and SS versus RA only). 
In the propensity score model, baseline demographics 
and response characteristics were compared between the 
cohorts (RA and SS versus RA only), and the absolute 
values of the standardized differences were estimated. The 
absolute value of the standardized difference of ≤ 0.1 for 
the overall population [17] was taken to indicate a negli-
gible difference in the mean or prevalence of a covariate 
between cohorts; variables with a standardized differ-
ence > 0.1 were included in the construction of the pro-
pensity score model.
Variables assessed included demographic and socioeco-
nomic characteristics, lifestyle factors, history of comor-
bidities, RA disease characteristics, previous and current 
RA therapy, RA disease activity and PROs. Patients with 
an SS diagnosis (patients with RA and SS) were compared 
with patients without an SS diagnosis (patients with RA 
only). For the subgroup analysis in patients who were anti-
CCP+, anti-CCP testing was performed by investigators 
and anti-CCP+ was defined as ≥ 20 units/mL. Statistical 
significance was estimated using Student’s t test for contin-
uous variables and Chi-square test for category variables.
Study outcomes
The primary outcome was the mean change in Clinical 
Disease Activity Index (CDAI) score from index visit to 
Month 12 in PSM patients [18]. The secondary outcome 
was mean change in PROs (modified Health Assessment 
Questionnaire [mHAQ], pain, fatigue, patient global 
assessment, EuroQol 5 dimensions [EQ-5D] index and 
morning stiffness) from index visit to Month 12 in PSM 
patients. Subgroup analyses were conducted in patients 
who were anti-CCP+ at index visit.
Results
SS data were available for 36,256 patients with RA, of 
whom 1901 met the inclusion criteria (Fig.  1). There 
were 454 pairs of patients randomly generated with either 
RA and SS or RA only by frequency matching based on 
RA duration (Fig. 1 and Supplementary Table S1). Due 
to residual cohort imbalance after frequency matching 
(Supplementary appendix), the frequency-matched cohorts 
were pooled and further refined by PSM. Of the 454 pairs 
of frequency-matched patients, 283 pairs of patients were 
PSM (Table 1 and Fig. 1). The baseline demographics, 
disease characteristics and PROs of PSM patients with 
RA, with and without SS, were generally well balanced. 
At baseline, 62–64% of patients were being treated with 
tumor necrosis factor inhibitors, 21–22% with other b/tsD-
MARDs and 16–17% with abatacept. At baseline, 56–59% 
of patients in each cohort were receiving methotrexate 
monotherapy.
Fig. 1  Selection of eligible patients for analysis. aYes/no to having 
SS. bAfter the first capture of SS data in patients with a diagnosis of 
no SS. cBetween patients with and without SS by biologic initiators. 
dInformed from frequency matching, based on logistic regression 
model predicting group (RA and SS versus RA only). b/tsDMARD 
biologic or targeted synthetic disease-modifying antirheumatic drug, 
CCP+ cyclic citrullinated peptide positive, RA rheumatoid arthritis, 
SS Sjögren’s syndrome
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Table 1  Baseline characteristics 
of the PSM RA cohort
Data are n (%) unless otherwise stated
a History of coronary artery disease, myocardial infarction, congestive heart failure requiring hospitaliza-
Patients with RA and 
SS (n = 283)
Patients with RA 
only (n = 283)
p value
Age, years, mean (SD) 58.4 (12.2) 58.7 (12.8) 0.712
Sex, female 235 (83.0) 235 (83.0) 1.000
Work status 0.945
 Full-time 103 (36.4) 107 (37.8)
 Part-time 33 (11.7) 29 (10.2)
 Disabled 42 (14.8) 46 (16.3)
 Retired 84 (29.7) 83 (29.3)
 Other 21 (7.4) 18 (6.4)
BMI, kg/m2, mean (SD) 30.2 (7.0) 30.5 (7.1) 0.699
Duration of RA, years, mean (SD) 10.5 (10.0) 10.3 (9.7) 0.834
Co-morbidities
 Hypertension 89 (31.4) 91 (32.2) 0.857
 CV  diseasea 32 (11.3) 31 (11.0) 0.894
 Malignancyb 29 (10.2) 31 (11.0) 0.785
 Diabetes 27 (9.5) 25 (8.8) 0.771
 Serious  infectionsc 24 (8.5) 24 (8.5) 1.000
 Asthma 18 (6.4) 15 (5.3) 0.590
 COPD 5 (1.8) 7 (2.5) 0.560
 ILD/pulmonary fibrosis 4 (1.4) 1 (0.4) 0.178
Anti-CCP+, n/m (%) 56/114 (49.1) 66/119 (55.5) 0.333
RF+, n/m (%) 91/137 (66.4) 80/144 (55.6) 0.062
Erosive disease, n/m (%) 74/216 (34.3) 64/197 (32.5) 0.703
Subcutaneous nodules, n/m (%) 69/283 (24.4) 73/283 (25.8) 0.698
Current b/tsDMARDs use 283 (100.0) 283 (100.0)
 TNFi 180 (63.6) 174 (61.5) 0.602
 Other b/tsDMARD 59 (20.8) 62 (21.9) 0.758
 Abatacept 44 (15.5) 47 (16.6) 0.731
Concomitant csDMARD use, n/m (%) 207/283 (73.1) 213/283 (75.3) 0.848
 MTX only 121 (58.5) 119 (55.9)
 Non-MTX csDMARD only 41 (19.8) 40 (18.8)
 MTX and non-MTX combination 39 (18.8) 46 (21.6)
 Non-MTX and csDMARD combination 6 (2.9) 8 (3.8)
Number of prior b/tsDMARDs 0.794
 0 116 (41.0) 121 (42.8)
 1 77 (27.2) 70 (24.7)
 ≥ 2 90 (31.8) 92 (32.5)
Number of prior csDMARDs 0.871
 0 16 (5.7) 16 (5.7)
 1 116 (41.0) 110 (38.9)
 ≥ 2 151 (53.4) 157 (55.5)
CDAI score, mean (SD) 24.0 (14.9) 24.1 (14.7) 0.922
PROs
 mHAQ, mean (SD) 0.5 (0.5) 0.6 (0.5) 0.389
 Patient pain, mean (SD)d 50.6 (27.0) 52.3 (27.3) 0.464
 Patient fatigue, mean (SD)e 53.6 (29.3) 56.2 (28.9) 0.299
 Patient global assessment, mean (SD) 47.8 (26.1) 50.0 (25.4) 0.303
 EQ-5D index, mean (SD)f 0.7 (0.2) 0.7 (0.2) 0.414
 Morning stiffness time, minutes, mean (SD)g 111.1 (199.1) 112.3 (195.5) 0.942
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RA disease activity
At the 12-month follow-up, mean (standard deviation [SD]) 
CDAI score was numerically higher in patients with RA and 
SS compared with patients with RA only (Table 2). At the 
12-month follow-up, the mean (SD) change in CDAI score 
from the index visit was numerically lower in patients with 
RA and SS compared to those with RA only (Fig. 2). These 
comparisons did not reach statistical significance.
Patient‑reported outcomes
At baseline, patients with RA and SS had lower mean (SD) 
PRO scores than patients with RA only (Table 1). How-
ever, at the 12-month follow-up visit, mean (SD) PRO 
scores were higher in patients with RA and SS compared 
with patients with RA only (Table 2), with the exception 
of mHAQ and EQ-5D index scores, which were similar in 
both cohorts. Mean (SD) patient pain, patient fatigue, and 
patient global assessment at the 12-month follow-up visit 
were significantly higher in patients with RA and SS com-
pared with patients with RA only (p = 0.014, p = 0.018 and 
p = 0.023, respectively). Morning stiffness at 12 months was 
numerically higher in patients with RA and SS compared 
with patients with RA only, but this was not statistically sig-
nificant. Mean changes from the index visit in pain, fatigue 
and patient global assessment were statistically significant 
(p = 0.002, p = 0.001 and p = 0.002, respectively), and two- 
to three-fold inferior (suggesting more impairment), for 
patients with RA and SS compared with patients with RA 
only (Fig. 2). The mean change in morning stiffness was 
numerically lower in patients with RA and SS compared 
with patients with RA only. The mean change in mHAQ 
was similar in both cohorts. There was no change in EQ-5D 
index score from index event until 12-month follow-up for 
patients with RA and SS, while the mean change for patients 
with RA only was marginally worse at 12 months.
Subgroup analyses in patients with anti‑CCP+ RA
Of the 283 PSM pairs, there were 122 patients who were 
anti-CCP+: 56 (45.9%) patients with RA and SS and 66 
(54.1%) patients with RA only (Fig. 1). In patients who 
were anti-CCP+, the mean (SD) change in CDAI score 
was similar between patients with RA and SS and those 
with RA only (Fig. 3). In patients who were anti-CCP+, 
the mean (SD) change in pain and fatigue was significantly 
lower in patients with RA and SS compared with patients 
with RA only (p = 0.048 and p = 0.003, respectively; Fig. 3). 
Although numerical differences were observed, there were 
no statistically significant differences in mean improvements 
in patient global assessment and morning stiffness outcomes 
between patients with anti-CCP+ RA and SS and those with 
anti-CCP+ RA only. In patients who were anti-CCP+, the 
tion, acute coronary syndrome, unstable angina, cardiac revascularization procedure, cardiac arrest, ven-
tricular arrhythmia, stroke, transient ischemic attack, or other CV event
b History of lung cancer, breast cancer, lymphoma, skin cancer (melanoma and squamous cell carcinoma), 
or other cancer
c Infection required hospitalization or IV treatment
d Patients with RA and SS, n = 282
e Patients with RA and SS, n = 271; patients with RA only, n = 237
f Patients with RA and SS, n = 262; patients with RA only, n = 228
g Patients with RA and SS, n = 251; patients with RA only, n = 247
BMI body mass index, b/tsDMARD biologic or targeted synthetic disease-modifying antirheumatic drug, 
CCP+ cyclic citrullinated peptide positive, CDAI Clinical Disease Activity Index; COPD chronic obstruc-
tive pulmonary disease, csDMARD conventional synthetic disease-modifying antirheumatic drug, CV car-
diovascular, EQ-5D, EuroQol 5 dimension, ILD interstitial lung disease, IV intravenous, mHAQ modified 
Health Assessment Questionnaire, MTX methotrexate, n/m number of patients/total number of patients with 
available data, PRO patient-reported outcome, RA rheumatoid arthritis, RF+ rheumatoid factor positive, 
SD standard deviation, SS Sjögren’s syndrome, TNFi tumor necrosis factor inhibitor
Table 1  (continued)
Table 2  Mean CDAI score and PROs at the 12-month follow-up
Data are mean (SD)
CDAI Clinical Disease Activity Index, EQ-5D EuroQol 5-dimension, 
mHAQ modified Health Assessment Questionnaire, PRO patient-
reported outcome, RA rheumatoid arthritis, SD standard deviation, SS 
Sjögren’s syndrome
Patients with RA 





CDAI 15.2 (13.4) 14.8 (12.8) 0.758
mHAQ 0.5 (0.5) 0.5 (0.5) 0.629
Patient pain 44.2 (29.0) 38.3 (28.1) 0.014
Patient fatigue 49.2 (30.1) 43.4 (28.5) 0.018
Patient global assess-
ment
42.4 (27.8) 37.1 (27.4) 0.023
EQ-5D index 0.7 (0.2) 0.7 (0.2) 0.982
Morning stiffness 
(min)
92.9 (172.7) 90.6 (209.0) 0.922
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mean change in mHAQ was the same in both cohorts; there 
was no change in EQ-5D index score from index event until 
12 month follow-up for patients with RA only, while the 
mean change for patients with RA and SS was marginally 
worse at 12 months.
Discussion
In this analysis of data from the large US Corrona RA reg-
istry, we compared RA disease activity and PROs among 
patients with RA, with and without SS, who initiated b/
tsDMARD treatment. Initially, patients with RA and SS or 
RA only were frequency matched by duration of RA. Sig-
nificantly fewer patients with RA and SS were in full-time 
employment and more were disabled or retired compared 
with patients with RA only. Patients with RA and SS were 
also more likely to have co-morbidities and to be taking sev-
eral treatments for RA. These results complement published 
data examining the effect of SS on quality of life [8, 19]. 
The symptoms of SS exert a burden on a patient that may 
impact physical and social functioning, which in turn may 
affect employment status. Combined with the burden of RA 
[20], SS may substantially affect a patient’s quality of life.
There is a paucity of published data investigating dis-
ease activity in patients with RA and SS, particularly from 
studies measuring cumulative disease activity with index 
dates defined by SS onset [6, 9, 15, 21–23]; only two of 
the aforementioned studies included a follow-up period [6, 
9]. The studies vary in size (82–1471 patients) [9, 22] and 
methods used for SS diagnosis, often utilizing a mixture 
of objective (e.g., Schirmer’s test) and subjective methods 
(e.g., physician exam and/or questionnaire from patient-
reported symptoms) [21–23]. Two cross-sectional obser-
vational studies found no relationship between SS status 
and RA disease activity, as measured by Disease Activ-
ity Score 28 (DAS28) using erythrocyte sedimentation 
rate or C-reactive protein, in patients with RA with and 
Fig. 2  Mean (SD) reduction in CDAI score and PROs from index 
visit to 12-month follow-up visit. p values estimated using Student’s 
t test and Chi-square test. CDAI Clinical Disease Activity Index, EQ-
5D EuroQol 5-dimension, mHAQ modified Health Assessment Ques-
tionnaire, PRO patient-reported outcome, RA rheumatoid arthritis, SD 
standard deviation, SS Sjögren’s syndrome
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without SS [22, 23]. It should be noted that the proportion 
of patients with RA and SS in these studies was small: 
n = 20/82 [22] and n = 11/307 [23]. In contrast, several 
studies have noted an association between SS and RA dis-
ease activity [9, 15, 21]. The analysis of 1471 patients with 
RA enrolled in a longitudinal RA registry revealed that 
patients with RA and SS (n = 415) experienced a longer 
duration of disease, higher RA disease activity (meas-
ured by RA disease activity index, CDAI and DAS28) at 
baseline and significantly lower reduction in RA disease 
activity at 12 months than patients with RA only [9]. In a 
study of 636 patients with RA (n = 232 patients with SS 
symptoms), DAS28 was significantly higher for patients 
with moderate and severe symptoms compared with 
patients with no symptoms of SS [21]. Similarly, among 
509 patients with RA (n = 74 patients with RA and SS), 
patients with RA and SS had significantly higher DAS28 
scores than patients with RA only [15].
To minimize selection bias in the current study, patients 
were PSM to account for variables associated with treatment 
response. The resulting cohorts (patients with RA and SS 
and patients with RA only) were generally well balanced in 
terms of baseline characteristics. At the 12-month follow-up 
visit, there were no significant differences in the change in 
clinical disease activity between patients with RA and SS 
and those with RA only; however, change in CDAI score 
after 12 months was numerically lower (suggesting greater 
impairment) in patients with RA and SS compared to those 
with RA only. The lack of association between SS status and 
RA disease activity in the present study is likely due to PSM; 
characteristics that are commonly seen with SS, and that are 
associated with RA disease activity, were accounted for in 
this analysis, but may not have been in the aforementioned 
studies, which did not use PSM [9, 15, 21].
Previous studies have demonstrated that patients with SS 
only (as opposed to patients with SS co-existing with another 
Fig. 3  Mean (SD) reduction in CDAI score and PROs from index 
visit to 12-month follow-up visit in the subgroup of patients with 
anti-CCP+ RA. p values estimated using Student’s t test and Chi-
square test. CCP+ cyclic citrullinated peptide positive, CDAI Clinical 
Disease Activity Index, mHAQ modified Health Assessment Ques-
tionnaire, PRO patient-reported outcome, RA rheumatoid arthritis, SD 
standard deviation, SS Sjögren’s syndrome
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autoimmune condition) experience pain and fatigue [24], as 
do patients with RA only [25]; therefore, it could reason-
ably be inferred that, when co-existing with RA, SS exacer-
bates these PROs. In this analysis, at the 12-month follow-
up visit, improvements in the majority of RA-related PROs 
were reduced in patients with RA and SS versus patients 
with RA only (suggesting more impairment). In accordance 
with this, several studies have demonstrated the additional 
burden of SS on patients with RA [9, 21, 23]. In an obser-
vational study, patients with RA with moderate or severe SS 
symptoms had significantly worse scores for mHAQ, pain 
and fatigue compared with patients with RA with no SS 
symptoms [21]. In a longitudinal registry analysis, patients 
with RA and SS experienced significantly higher multidi-
mensional (MD) HAQ fatigue scores at baseline compared 
with patients with RA only [9]. After 12 months, patients 
with RA and SS experienced numerically lower reductions 
in MDHAQ fatigue scores than patients with RA only [9]. In 
addition, an observational study demonstrated that patients 
with RA and SS experienced numerically greater pain (vis-
ual analog scale) scores compared with patients with RA 
only [23]. Interestingly in our analysis, the differences in two 
PRO measures, mHAQ and EQ-5D index, between patients 
with RA and SS and patients with RA only, were marginal. 
However, the mHAQ and EQ-5D index questionnaires are 
completed by patients and would likely be impacted by 
underlying RA disease status.
Patients with RA who are ACPA+ are more likely to 
have a more severe disease course than patients who are 
ACPA− [13]. A study of Greek patients with RA concluded 
that the presence of anti-CCP antibodies was associated 
with extra-articular manifestations, such as serositis and 
pulmonary fibrosis [14]. In several studies, the proportion 
of patients with anti-CCP antibodies has been found to be 
higher in patients with RA and SS compared with patients 
with RA only (67.6–77.8% versus 59.4–71.9%) [6, 9, 15]. 
Therefore, we sought to clarify if the presence of SS would 
exacerbate the disease course further in anti-CCP+ patients. 
Contrary to previous research [6, 9, 15], in the current study, 
the proportion of patients with anti-CCP antibodies was 
lower in patients with RA and SS compared with patients 
with RA only (49.1% versus 55.5%); however, it should be 
noted that not all patients had measures reported. RA dis-
ease activity and PRO results were similar in the subgroup 
of patients with RA who were anti-CCP+, indicating that 
SS status did not affect outcomes differently in this patient 
population.
The biologic pathways associated with the differences in 
patients with RA with, and without, dry eyes and mouth (SS) 
are not clear [26–28]. However, the results of the current 
study do suggest that physicians may wish to consider SS 
status in the management of patients with RA; in particular, 
there may be a need for closer monitoring and assessment 
of response to treatment. More aggressive treatment of SS 
with RA may be needed.
This analysis has several strengths, namely the Corrona 
registry is the largest disease registry in the US that collects 
data directly from both providers and patients at the time of 
a routine clinical encounter. This allowed for patients with 
RA and SS or RA only to be selected from a broad popula-
tion, ensuring satisfactory pairing [29]. The Corrona regis-
try does include a wide variety of rheumatology practices 
participating throughout the country (rural and urban areas, 
academic and private settings) and brings access to broad 
geographic locations and patients with diverse sociodemo-
graphic origins. Prior analyses compared Medicare patients 
with RA enrolled in Corrona to those who are not part of the 
registry and found similar demographic and co-morbidity 
characteristics, supporting the generalizability of the Cor-
rona registry [29]. Data are collected at regular intervals, 
which enabled us to evaluate outcomes at two different time 
points. Advanced epidemiological methods (e.g., PSM) were 
used to compare responses between patients with and with-
out SS where selection bias may have existed. The presence 
of SS was captured on the provider form and is considered a 
critical field of data for Corrona. The results from this obser-
vational study in US patients complement previous studies 
[8, 9, 19, 21–23].
As opposed to previously reported studies, bias was 
minimized by PSM of the two cohorts (RA and SS versus 
RA only) by factors known to be associated with treat-
ment response (e.g., age, sex, CDAI score, number of prior 
biologics, work status, history of co-morbidities and RA 
disease characteristics). Another limiting factor was that 
patients included in the registry were diagnosed by differ-
ent rheumatologists across the US; diagnosis of SS was at 
the discretion of the treating physician (SS associated with 
RA: yes/no) and rheumatologists may have used a variety 
of mostly historical clinical signs and symptoms rather 
than objective testing (i.e., Schirmer’s test). Nevertheless, 
we believe that the manner in which these data were col-
lected reflects real-world clinical practice with the reporting 
of dry eyes and/or mouth not associated with medications 
or mouth breathing during the night. Additionally, patients 
in the RA-only cohort also required a questionnaire entry 
for SS associated with RA (yes/no), potentially leading to 
under-ascertainment.
In this large US patient population initiating b/tsDMARD 
treatment, patients with RA only had greater improvements 
in RA disease activity and PROs than those with RA and 
SS; similar results were shown in anti-CCP+ patients. Phy-
sicians may wish to consider SS status when managing 
patients with RA; specifically, patients with RA and SS may 
require closer monitoring and more aggressive intervention 
to improve their disease experience than patients with RA 
only. Additional studies are needed to further understand the 
1247Rheumatology International (2020) 40:1239–1248 
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biological pathways involved in SS co-existing with RA, and 
subsequently to provide targeted treatment options for this 
population of patients.
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